Shanghai, China, April 8, 2021 – Asieris Pharmaceuticals announced today that Dr. Tie-Lin Wang has been appointed as Senior Vice President, Head of Discovery Chemistry and Pre-Clinical Development. He will report to Dr. Kevin Pan, Founder and CEO of Asieris.
Dr. Wang has a proven track record in drug discovery over the past two decades. He is well recognized for his broad expertise in R&D management and strong leadership skills. Previously, he served as Chief Scientific Officer at Luoxin Pharmaceuticals (Shanghai), where he successfully built an R&D team of nearly 200 professionals. Under his leadership, multiple drug candidates have been advanced to clinical trials. Dr. Wang also served as Vice President of drug discovery at ChemPartner where he was in charge of multiple collaborative projects with multinational pharmaceutical companies, with one compound is currently in a Phase II clinical trial. Before returning to China, Dr. Wang was an Associate Director at Exelixis, and led his team to advance four compounds into clinical development stages. Among them, Minnebro has been approved and launched in Japan for the treatment of essential hypertension.
Dr. Wang received his Ph.D. degree in organic chemistry from Shanghai Institute of Organic Chemistry, Sinica Academia. His postdoctoral training in the US included his research in the lab of Sir Derek Barton, a Nobel laureate, at Texas A&M University. As a co-inventor, he has more than 70 granted patents.
“We are excited to have Dr. Wang join our leadership team,” said Dr. Kevin Pan, Founder and CEO of Asieris. “Dr. Wang will bring in his expertise and strengthen our R&D capabilities in drug discovery, as a key initiative to empower us on the journey of achieving our five-year strategic goals. Dr. Wang’s extensive experiences and successful track record will help us accomplish our plans as Asieris is striving to become a leader in treating genitourinary cancers and related diseases.”
About Asieris
Asieris strives to become a leading pharmaceutical company focusing on genitourinary tumors and related diseases. Asieris adheres to a growth strategy driven by in-house research and development, supplemented by in-licensing, to rapidly establish a leadership position in the field of focus. Asieris currently has multiple products under late-stage clinical development and owns proprietary platforms for the discovery of new antitumor and antimicrobial drugs. Asieris has offices and operations in Shanghai, Beijing, and Taizhou City of Jiangsu Province in Mainland China, Philadelphia in the US, and London in UK.
For more information, please visit us at asieris.com.
